Pacifico Yokohama, Japan      October 14 (Wed.) – 16 (Fri.), 2020

To Pre-register for the seminars, please complete the visitor registration first.
*If you already completed above, you can proceed your seminar registration from your visitor account.
(Seminar Registration will start from Sep. 16th)
✔ Register Now → Account Login

Organizer

Oct.14(Wed.)      10  :  00  ~  11  :  30

F203-206
【K-1】 Keynote Lecture
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)

Keynote Lecture 

Translating IL-6 biology into effective treatment

Prof. Tadamitsu Kishimoto

Specially Appointed Professor
Immunology Frontier Research Center (IFReC), Osaka University

In Japanese

Shigeru Omi

President of JAPAN Community Health care Organization (JCHO)

Japan's Bioeconomy Strategy 2020 (tentative)

Osamu Nagayama

President, Japan Bioindustry Association

Oct.14(Wed.)      12  :  00  ~  13  :  00

【S-2】 LEO Pharma K. K.
Pre-Registration required Online Seminar

Dreaming the future of life sciences through the alliance of LEO Pharma, CIC Tokyo and Venture Cafe Tokyo 

LEO Pharma is a Denmark-based pharmaceutical company with strengths in the field of dermatological diseases. CIC Tokyo opened up the largest innovation hub in Tokyo in October. Venture Cafe Tokyo has established a huge network of innovators in 12 locations around the world. The borderless alliance of these three parties aims at fostering a startup ecosystem and building a strategy for innovation and serendipity based on their know-how, space and network. Please watch our session and join our powerful network!

LEO Science & Tech Hub - Better tomorrow for patients with skin diseases through cutting-edge science & technologies

Dr. Taruho KURODA

Director
LEO Science & Tech Hub Tokyo
LEO Pharma K. K.

In Japanese

CIC Tokyo - The birth of globally connected innovation hub in Tokyo

Prof. Takaaki UMEZAWA

Chairman
CIC Japan

In Japanese

Venture Cafe Tokyo - Connecting people to make things happen in life science industry

Prof. Yasuhiro YAMAKAWA

Executive director
Venture Cafe Tokyo

In Japanese

PANEL DISCUSSION

Joint session by LEO Pharma, CIC Tokyo & Venture Cafe Tokyo - Towards Creation of a Startup Ecosystem【English session with Japanese subtitle】

Dr. Tord LABUDA

Vice President
R&D Asia-Pacific hub
LEO Pharma A/S

In Japanese

Prof. Takaaki UMEZAWA

Chairman
CIC Tokyo

In Japanese

Prof. Yasuhiro YAMAKAWA

Executive Director
Venture Café Tokyo

In Japanese

Dr. Taruho KURODA (Moderator)

Director
LEO Science & Tech Hub Tokyo
LEO Pharma K. K.

In Japanese

Organizer

Oct.14(Wed.)      13  :  00  ~  14  :  30

F203-204
【O-3】 COVID-19: Forefront of Diagnosis (tentative)
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)

COVID-19: Forefront of Diagnosis (tentative)  

Coordinator

Prof. Tatsuhiko Kodama

Research Center for Advanced Science and Technology, The University of Tokyo

Antibody Testing for SARS-CoV-2(COVID-19) and Infection Control

Prof. Kawamura Takeshi

Associate Professor
Isotope Science Center
The University of Tokyo

In Japanese

Laboratory diagnosis methods for COVID-19

Prof. Kimura Hirokazu

Contribution of human host genomics to prevention of COVID-19 pandemic

Prof. Yukinori Okada

Professor
Department of Statistical Genetics
Osaka University Graduate School of Medicine

Oct.14(Wed.)      13  :  30  ~  14  :  30

F201-202
【S-1】 Noster Inc.
Pre-Registration required Simultaneous interpretation

Creating innovative therapeutic agents by controlling the gut microbiome 

Dysbiosis is frequently reported to be associated with illnesses such as inflammatory bowel disease (IBD), obesity, cancer, etc. Immunoglobulin A (IgA) is the antibody secreted into the intestinal lumen. IgA plays a critical role in the defense against pathogens and in the maintenance of intestinal homeostasis through gut microbial control. However, how secreted IgA regulates gut microbiota is not completely understood. Our main question is what kind of bacterial molecule an intestinal high-affinity IgA recognizes and targets. To address this question, we generated hybridomas from IgA producing cells in small intestine of wild type mice. As a candidate of efficient gut microbiota modulator, we selected a W27 IgA. W27 IgA selectively inhibited the in vitro growth of bound bacteria, including Escherichia coli (E. coli), suggesting that W27 IgA has an ability to improve the intestinal environment. Thus, W27 IgA oral treatment is a potential remedy for a variety of diseases associated with dysbiosis, acting through restoration of the host-microbial symbiosis.
Moreover, the latest findings of gut microbial research such as intestinal bacterial metabolites (postbiotics) as an alternative state dual controller that simultaneously controls disease state and intestinal flora, and future drug discovery based on these new findings will be introduced.

Gut microbial metabolites (postbiotics) as an alternative state dual controller that simultaneously controls disease state and intestinal flora

Prof. Jun Ogawa

Professor
Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University,

In Japanese

Intestinal IgA as a gut microbial modulator

Prof. Reiko Shinkura

Professor
Laboratory of Immunology and Infection Control Institute for Quantitative Biosciences The University of Tokyo

In Japanese

Noster company’s information

Dr. Yasunori Yonejima

Research Manager
R&D Division Microbiome group
Noster Inc.

In Japanese

Oct.14(Wed.)      14  :  00  ~  15  :  30

G303-304
【S-3】 Manufacturing Technology Association of Biologics
Pre-Registration required

Manufacturing Technology Association of Biologics 

The Manufacturing Technology Association of Biologics (MAB) developed integrated technology platforms for the biologics production. Technology Association is non-profit mutual benefit organization (cooperation) and this association focused on manufacturing of biologics including therapeutic antibody, recombinant protein, and gene therapy. In this presentation, we will introduce the research and developments (5 young researchers: Dr. Yamano-Adachi, Dr. Onitsuka, Dr.Kawabe, Dr.Yoshimoto, Dr. Sugiyama and 7 organizations: Chitose Laboratory Corp., Able Corporation, Fujimori Kogyo Co.,Ltd., Fuji Film Wako Pure Chemical Corporation, YMC Co.,Ltd., National Institute of Advanced Industrial Science and Technology / MAB, Sumitomo Bakelite Co.,Ltd.) under AMED (Japan Agency for Medical Research and Development) project in manufacturing technologies for therapeutic protein and gene therapy and discuss about next-generation manufacturing platform in biologics production.

Next-generation platform manufacturing~From therapeutic antibody to cell and gene therapy

Dr. Omasa Takeshi

Manufacturing Technology Association of Biologics Project Leader/ Graduate School of Engineering, Osaka University Professor/ Tokushima University Visiting Professor/ Kobe University Visiting Professor

In Japanese

Organizer

Oct.14(Wed.)      15  :  00  ~  17  :  00

F203-204
【O-5】 Emergency Discussion: Current Situation of COVID-19 Vaccination (tentative)
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)

Emergency Discussion: Current Situation of COVID-19 Vaccination (tentative) 

Coordinator

Dr. Kawaoka Yoshihiro

professor
Division of Virology
Institute of Medical Science University of Tokyo

Activity by Japanese Regulatory Authorities to Evaluate the Efficacy and Safety of COVID-19 Vaccines

Mr. Yasuhiro Araki

Development of DNA Vaccine Against Novel Corona Virus

Prof. RYUICHI MORISHITA

Professor
Department of Clinical Gene Therapy
Osaka University

In Japanese

Vaccine development for COVID-19

Dr. Fumihiko TAKESHITA

Development of an Inactivated Vaccine for COVID-19

Dr. Kengo Sonoda

General Manager
Development Department, R&D Division
KM Biologics Co., Ltd.

In Japanese

Dr. Ryuichi Kiyama

Senior Executive Officer, Senior Vice President
Pharmaceutical Research Division
Shionogi & Co., Ltd.

In Japanese

【Recorded Presentation】
Development of an Ad26 vector based COVID-19 vaccine at Janssen

Dr. Hanneke Schuitemaker

Global Head of Viral Vaccine Discovery and Translational Medicine,
Viral Vaccines
Johnson & Johnson's Janssen Vaccines & Prevention

Dr. Tadahiro Fujino

Head of Clinical Science, R&D
Janssen Pharmaceutical K.K.

Organizer

Oct.15(Thu.)      10  :  00  ~  11  :  30

F203-204
【O-7】 COVID-19: Forefront of Treatment (tentative)
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)

COVID-19: Forefront of Treatment (tentative) 

At present, our knowledge of the treatment of COVID-19 with antiviral drugs is limited. Remdesivir is an RNA-dependent RNA polymerase inhibitor that has shown widespread activity against RNA viruses. It was approved for use in Japan on May 7, 2020, under a special approval system.
COVID-19 is known to rapidly develop into a state of pneumonia and worsen respiratory failure from about 7-10 days after onset. It is thought to be a mechanism of dysregulation of the immune system, resulting in abnormal release of cytokines. This is the reason for the use of immunomodulating drugs. In the RECOVERY study of dexamethasone, a total of 2104 patients were randomized to receive 6 mg of dexamethasone once daily (orally or intravenously) for 10 days, compared with 4321 patients randomized to conventional therapy alone, and found that patients who received dexamethasone-administered ventilation were less likely to have There was a one-third reduction in death in patients who received oxygen (rate ratio 0.65 [95% confidence interval 0.48 to 0.88]; p=0.0003) and a one-fifth reduction in death in patients receiving oxygen (0.80 [0.67 to 0.96]; p=0.0021).

Coordinator

Dr. Ohmagari Norio

Director
Disease Control and Prevention Center
National Center for Global Health and Medicine

AMED’s role for R&D related to combating the novel coronavirus Disease (COVID-19)

Mr. Katsufumi JO

Executive Director
Japan Agency for Medical Research and Development

In Japanese

Remdesivir: the first approved treatment for SARS-CoV-2 infection in Japan

Dr. Masayuki Omote

Executive Director, Clinical Research
Gilead Sciences KK

In Japanese

Anti-IL-6 receptor antibody Actemra for the treatment of patients with severe COVID-19 pneumonia

Dr. Minoru Watanabe

Vice President, Head of Project & Lifecylcle Management Unit
Project & Lifecylcle Management Unit
Chugai Pharmaceutical Co., Ltd.

In Japanese

Organizer

Oct.15(Thu.)      13  :  30  ~  15  :  00

F203-204
【O-11】 How does artificial intelligence change the medical and pharmaceutical industries?
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)

How does artificial intelligence change the medical and pharmaceutical industries?
 

The progress of artificial intelligence (AI) technology, represented by the deep learning method, accelerates its application in the drug development and medical fields. Actually, there are several cases reported, in which AI selects the best compound for the target molecule of interest during the drug discovery process and AI finds a novel pharmacological activity of a known pharmaceutical for the drug repositioning purpose. In the clinical field, it is also recognized that AI are contributed to pathological diagnosis of diseases, patient healthcare management, hospital works and so on. These facts no doubt elevate our expectation that drug research and development process and practical medical operations will be more effective, speedy and precise by penetrating AI technology into the drug research and medical fields. In this session, we will introduce successful examples and strategies of the application of AI in these fields and also would like to discuss how AI changes the pharmaceutical and medical industries.

Coordinator

Dr. Kimura Toru

Member, Board of Directors, Senior Executive Officer, CSO
Sumitomo Dainippon Pharma Co., Ltd.

Re-energising Small Molecule Drug Discovery by AI: From Discovery Concept to Clinical Candidate

Dr. Daisuke Tanaka

Representative Director
Exscientia KK

In Japanese

Utilizaton of AI in the field of health, labour and welfare

Mr. Shinichi TAKAE

Director for Research Planning
Health Science Diision of Minister's Secretariat
Ministry of Health, Labour and Welfare

In Japanese

【Recorded Presentation】

Dr. Jason LaBonte

Organizer

Oct.15(Thu.)      15  :  00  ~  16  :  30

G301-302
【O-14】 [Forefront of biopharmaceutical production] Is there enough human resources for development and manufacturing of biologics in your organization? ~ Under the situation that modalities of biopharmaceuticals are diversifying~
Pre-Registration required

【Forefront of biopharmaceutical production 】Is there enough human resources for development and manufacturing of biologics in your organization? ~ Under the situation that modalities of biopharmaceuticals are diversifying~ 

It has been pointed out that technological development and human resource development for biopharmaceutical manufacturing are important even in Japan under the situation that modalities of biologics are diversifying. From the same perspective, the importance of human resource development can be seen in the policy recommendations of the Japan Pharmaceutical Manufacturers Association Biopharmaceutical Committee. In this session, we will review the direction of next-generation manufacturing technological innovation in response to the diversification of modalities and the utilization of digital technology for bioproduction, and clarify the human resources image required for biopharmaceutical manufacturing in the future.

Coordinator

Prof. Uchida kazuhisa

Kobe University

Needs for human resources to develop and manufacture biopharmaceuticals and regenerative medicine -from survey results for companies

Mr. Yoshihiro Watanabe

Chairperson of Subcommittee on Policy Issues
Biopharmaceutical Committee
Japan Pharmaceutical Manufacturers Association

In Japanese

Training for research and development of biologics in Biologics Center for Research and Training (BCRET)

Dr. Satoshi Toyoshima

Representative Director
Biologics Center for Research and Training

In Japanese

Digitalizing Biopharma R&D
- What type of skills are needed in the industry?

Mr. HIDEKI SHIMOHIRO

Managing Director
Genedata KK

In Japanese

Prof. Dohda Takeaki

大阪大学

In Japanese

Oct.15(Thu.)      15  :  00  ~  17  :  00

F201-202
【S-9】 Okinawa Science and Technology Promotion Center
Pre-Registration required

Okinawa Initiative on Infectious Diseases and Regenerative Medicine. 

Developing diagnostic test for human papillomavirus (HPV)-related cancer

Dr. Taro Ikegami

Assistant Professor
Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine
University of the Ryukyus

In Japanese

Practical use of high-performance VHH antibodies and natural bacteriophage bank for pharmaceuticals and quasi drugs.

Dr. Akikazu Murakami

Chief executive officer
RePHAGEN Co., Ltd.

In Japanese

A Concern on COVID-19.What we should do after COVID-19

Dr. Kobayashi Nobuyuki

President & CEO
AVSS Co.Ltd

In Japanese

FDA Approval of the World's First Cotton-like Bone void filler, and Application to the Stem Cell Extraction / Culture Sheet with Bioabsorbable property.

Dr. Masashi Makita

Director of Laboratory
ORTHOREBIRTH Co., Ltd

In Japanese

Regenerative medicine research at the University of the Ryukyus

Prof. Yusuke Shimizu

Professor
Department of Plastic and Reconstructive Surgery Graduate School of Medicine
University of the Ryukyus

In Japanese

Development status and future development of cell culture substrate for regenerative medicine

Mr. Yasutoshi Nishikawa

President & CEO
ORTHOREBIRTH Co., Ltd

In Japanese

Organizer

Oct.16(Fri.)      9  :  30  ~  11  :  30

F203-204
【O-17】 Future of Cancer Genomic Medicine
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)

Future of Cancer Genomic Medicine 

Coordinator

Executive Director/Director, Research Institute/Director, Center for Cancer Genomics and Advanced Therapeutics
National Cancer Center

Precision Cancer Medicine in Japan; current status and future perspective

Prof. Hiroshi Nishihara

Professor
Genomics Unit, Keio Cancer Center
Keio University School of Medicine

In Japanese

Prof. Takahiro Ochiya

Gene panel test reimbursed by the universal health coverage system and data accumulation in C-CAT

Dr. Takashi Kohno

【Recorded Presentation】
Cancer evolution, immune evasion and metastasis.

Prof. Charles Swanton

Senior Group Leader
Cancer Evolution and Genome Instability Laboratory,
The Francis Crick Institute

Organizer

Oct.16(Fri.)      12  :  00  ~  13  :  30

F201-202
【O-19】
Pre-Registration required

What is needed for future biotech venture business growth? 

Coordinator

Prof. KUNIO ITO

HITOTSUBA SHI Unibersity, Graduate School of Business Adoministration

Mr. Tetsuya TANAKA

Director
Bio-Industry Division, Commerce and Service Industry Policy Group
Ministry of Economy, Trade and Industry

In Japanese

Mr. Daisuke TANAKA

Ministry of Health, Labour and Welfare

In Japanese

Mr. Tadahisa KAGIMOTO

Chairman and CEO
HEALIOS K.K.

In Japanese

Mr. Ken TAKANASHI

Executive Vice President Chief Operating Officer
Shin Nippon Biomedical Laboratories, Ltd.

In Japanese

Mr. Hiroyuki HASEGAWA

Executive Officer General Manager
Mitsubishi UFJ Capital Co., Ltd.

In Japanese

Mr. Miyuki TANABE

Supporter
Medical Innovation Support Office

In Japanese

Organizer

Oct.16(Fri.)      15  :  00  ~  16  :  30

F201-202
【O-20】 Post-Corona Business Model -Supply Chain/Value Chain Restructuring-
Pre-Registration required

Post-Corona Business Model -Supply Chain/Value Chain Restructuring- 

Coordinator

Prof. TODA Yuzo

President & Representative Director / Professor
Toda Research Laboratory / Fujita Health University

Drug Development with COVID-19 - the impact and the challenge-

Dr. Hironobu Saito

Corporate Officer, Head of Medical Affairs Division
DaiichiSankyo Co.,Ltd.

In Japanese

TBC

Mr. Tetsuya Tanaka

Director, Bio-Industry Division
Commerce and Service Industry Policy Group
Ministry of Economy, Trade and Industry

In Japanese

Organizer

Oct.16(Fri.)      15  :  30  ~  17  :  00

F205-206
【O-21】
Pre-Registration required

Evolution of the Modalities in Drug Discovery  

In view of the diversities and the changes in the drug discovery process, we start JBA Study group on Platform Technology for New Modalities in Drug Discovery. The activities are promoted with the three pillars of (1) smeWG activities, public relations, lectures, (2) enlightenment activities, and (3) activities for policies and proposals by experts, and in particular, (1) smeWG activities are positioned as the core activities. As for drug discovery modalities, we are promoting smeWG activities of next-generation antibody medicine, nucleic acid medicine, and gene & cell therapies, which are most requested by the study group members. As for the drug discovery, discussions are proceeding from three elements of therapeutic technology (modality), disease (biology), and platform (IT, production technology) from the points of view of the perspectives of technology, regulation, and business. These activities are being carried out assuming a 10-year vision with the national strategy, Bio-strategy area sixth (biomedicines), in mind.

Coordinator

Dr. Hitoshi Kuboniwa

Corporate Advisor
Chugai Pharmaceutical Co., Ltd.

【Recorded Presentation】
AI Technology and New Modality
〜Seamless New Medical Era〜

Mr. EIKI Norikazu

EIKI CONSULTING, LLC

In Japanese

Prof. Takeshi Wada

Gene Cell Therapy -Current and Futureー

Mr. MASANOBU KIMURA

【S-12】 Hitachi, Ltd.
Pre-Registration required Online Seminar

Hitachi Group’s cell manufacturing solutions 

Practical application of regenerative medicine and cell-based therapy is accelerating, for example, four products including CAR-T have been approved since 2019. However, there are some problems to provide a stable supply of high quality cells. Hitachi group develops various products and services, and provides solutions for industrialization of the therapy. We introduce an automated cell culture equipment for mass production, a cell analysis, sorting system for selecting high quality cells, and a cell processing facility.

Coordinator

Dr. Jun Otomo

Chief Engineer
Advanced Medical Solution Center, Analytical Systems Division, Healthcare Business Division, Smart Life Business Management Division
Hitachi, Ltd.

Ms. Akane Hongo

Regenerative Medicine Solution Group, Advanced Medical Solution Center, Analytical Systems Division, Healthcare Business Division, Smart Life Business Management Division
Hitachi, Ltd.

In Japanese

Dr. Sadao Ota

Associate professor
Research Center for Advanced Science and Technology
The University of Tokyo

In Japanese

Application of Ghost Cytometry in Cell Therapy

Mr. Waichiro Katsuda

CEO
ThinkCyte, Inc

In Japanese

Ms. Yoshimi Sugahara

Front Solutions Division, Front Engineering Dept.
Hitachi Plant Services Co., Ltd.

In Japanese

Organizer

Oct.14(Wed.)      15  :  00  ~  16  :  30

F205-206
【O-4】 The forefront of research and development of regenerative medical products
Pre-Registration required

The forefront of research and development of regenerative medical products 

To date, 9 regenerative medical products have been approved in Japan. New products have been approved every year since 2018, and such R&D activities are accelerating. Efforts to address the challenges toward the industrialization of regenerative medicine have become more and more important. In this session, we will invite two experts who are working on the front line of the space and have commercialized an autologous human somatic stem cell-based product and a cell-based gene therapy product, respectively. They will introduce summaries of the developments, post marketing operations, future prospects and issues regarding the two different modalities. We will expect that their experiences will catalyze active discussions with respect to the challenges of regenerative medicine.

Coordinator

Mr. Suzuki Kunihiko

Member of the Board/Vice Chairperson
Forum for Innovative Regenerative Medicine

Development of Regenerative Medical Product "Stemirac®" for the therapy of Spinal Cord Injury


Mr. Yoshihiro Yoshikawa

NIPRO CORPORATION

In Japanese

Development of Gene Therapy in Novartis

Dr. Tohru Hirose

Director, Head of Global Drug Development Division
Global Drug Development Division
Novartis Pharma K.K.

In Japanese

Organizer

Oct.15(Thu.)      10  :  00  ~  11  :  30

G301-302
【O-9】 Challenges and Future of the Supporting Industry that help the Regenerative Medicine market.
Pre-Registration required

Challenges and Future of the Supporting Industry that help the Regenerative Medicine market. 

There are still many issues to be solved in the steady progress of regenerative medicine, and cooperation among all stakeholders is vital for further progress. In this session, following the lectures on japan and overseas efforts in regulations and quality, we invited experts from different fields and organize a panel discussion to discuss how supporting industries can support regulations and quality. Catch up on advanced cases in Japan and abroad regarding regulations and quality of regenerative medicine, and discuss actions that supporting industries should take as a guidepost for industrialization of regenerative medicine.

Coordinator

Mr. Kazuhiro Takekita

President
Hyperion Drug Discovery Co., Ltd.

Domestic and international regulations on raw materials and manufacturing of regenerative medical products

Dr. Yoji Sato

Head
Division of Cell-Based Therapeutic Products
National Institute of Health Sciences

In Japanese

【Recorded Presentation】
The UK cell and gene therapy ecosystem

Dr. Hoshiya Hidetoshi

Board Director
FuReMIC Therapeutics K.K.

In Japanese

Mr. Ryo Hanamura

Principal
Arthur D Little Japan

In Japanese

Legal requirements of raw materials for regenerative medicine

Dr. TOSHIHIKO KAMINUMA

Senior Manager
Custom Biotech
Roche Diagnostics KK

In Japanese

Luncheon

Oct.15(Thu.)      12  :  00  ~  13  :  00

F201-202
【L-1】 TAKARA BIO INC.
Pre-Registration required

TAKARA BIO INC. Luncheon Seminar 

TAKARA BIO INC.

In Japanese

Mr. Masahiro Tsuji

Center for Research and Development Strategy (CRDS), Japan Science and Technology Agency (JST)

In Japanese

Oct.15(Thu.)      13  :  30  ~  14  :  30

G301-302
【S-7】 Kanagawa Prefectural Government
Pre-Registration required

From Kanagawa to the World ! In order to accelerate the social implementation of regenerative medicine and cell therapy, This is the first system that we share facilities for the cell culture and processing at the Life Innovation Center finally started operation. 

Coordinator

Mr. Yoshiyuki Makino

Kanagawa Prefectural Government

Mr. Yoshiyuki Makino

Kanagawa Prefectural Government

In Japanese

Prof. Masaya Nakamura

Professor
Keio University School of Medicine

In Japanese

Ms. Shizuka Akieda

CEO
Cyfuse Biomedical K.K.

In Japanese

Mr. Ryuta Nomura

Chairman of the Board
Central Institute for Experimental Animals

In Japanese

Oct.15(Thu.)      13  :  30  ~  14  :  30

F201-202
【S-5】 Patheon by Thermo Fisher Scientific
Pre-Registration required

Patheon CDMO services updates ( Viral Vector services / Biologics )  

TBC

Oct.16(Fri.)      10  :  00  ~  11  :  00

F205-206
【S-11】 TAKARA BIO INC.
Pre-Registration required

TAKARA BIO INC. Sponsored Seminnar
Development updates on viral vector manufacturing and quality control for gene therapies 

Coordinator

Dr. Junichi Mineno

Takara Bio Inc.

Prof. Takashi Okada

Director/Professor
Center for Gene and Cell Therapy
The Institute of Medical Science, The University of Tokyo

In Japanese

Prof. Susumu Uchiyama

Professor
Macromolecular Biotechnology, Department of Biotechnology
Graduate School of Engineering, Osaka University

In Japanese

Organizer

Oct.16(Fri.)      11  :  30  ~  13  :  00

F205-206
【O-18】 The significance and problems of the early and conditional approval system - Is this system right or wrong?
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)

The significance and problems of the early and conditional approval system - Is this system right or wrong?   

The early and conditional approval system is an innovative regulation that Japan was the first in the world to start. It is a suitable regulation for regenerative medicine, such as being approved early and being skilled in medical practice after commercialization, which is expected to produce even better results, but has also received criticism from overseas. In this symposium, we would like to welcome performers and panelists to include ministries, academia and pharmaceutical companies utilizing the system, and stakeholders who are objective about the system, and discuss how to position and utilize this system, and how to disseminate it overseas.

Coordinator

Dr. HATA KEN-ICHIRO

Representative Director,Chairman
Forum for Innovative Regenerative Medicine

How Japan Leads the Global Regenerative Medicine Market

Mr. Colin Novick

Managing Director
CJ PARTNERS Inc.

In Japanese

Current status and prospects of ’Conditional and Time-limited approval system’ for regenerative medicine.

Mr. Sameshima Tadashi

Director
Terumo Corporation

In Japanese

Quality Life Cycle of Regenerative Medical Products and the Conditional Marketing Authorization System in Japan

Dr. Yoji Sato

Head
Division of Cell-Based Therapeutic Products
National Institute of Health Sciences

In Japanese

Regulatory Perspective on the conditional and time-limited authorization

Dr. Daisaku Sato

Associate Center Director for Regulatory Science
Pharmaceuticals and Medical Devices Agency

Organizer

Oct.16(Fri.)      13  :  30  ~  15  :  00

F203-204
【O-16】 Update in iPS Cell Research
Pre-Registration required

Update in iPS Cell Research 

This year's focus will be on whether the production and supply of iPS cell lines, which were transferred to public interest corporations from April 2020, will start smoothly and form the basis of regenerative medicine in Japan. Also, is it possible to form a new industrial base of regenerative medicine by transferring cell lines to companies? Clarify the actual situation and prospects through lectures and panel discussions.

Coordinator

Mr. Mitsuru Miyata

CEO
Miyata Insitute of Technologies,KK

CiRA Foundation ~ Translating iPS Cells to Clinical Application

Ms. Takasu Naoko

Executive Director
CiRA Foundation

In Japanese

Organizer

Oct.15(Thu.)      9  :  30  ~  11  :  30

F205-206
【O-8】 Possible future of healthcare industry
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)

Possible future of healthcare industry 

With the realization of a healthy and long-lived society becoming increasingly important worldwide, we will discuss the approach to healthcare as an industry and what kind of society we aim to achieve based on lectures from experts.

Coordinator

Dr. Katsunori Matsuoka

Special Emeritus Advisor
National Institute of Advanced Industrial Science and Technology

ICT in healthcare

Prof. Ryozo Nagai

President
/ President,Jichi Medical University

In Japanese

【Recorded Presentation】
Creating a World Without Disease

Dr. Murray McKinnon

Global Head,
World Without Disease Accelerator,
Janssen Research & Development

Transformation from a pharmaceutical company to a healthcare company

Dr. Ryo Shimizu

Executive Officer Chief Digital Officer Vice President,Head of Digital Transformation Department
Mitsubishi Tanabe Pharma Corporation

In Japanese

TBC

Oct.15(Thu.)      13  :  30  ~  14  :  30

F205-206
【S-6】 The National Institute of Advanced Industrial Science and Technology (AIST)
Pre-Registration required

Technology development to realize high-quality, high-performance, and high-precision diagnosis and treatment of COVID-19 

AIST considers COVID-19 prevention and control to be one of the most important issues and is carrying out research and development from various approaches.
In this seminar, we will introduce our research towards the realization of high-quality, high-performance, highly accurate diagnosis and treatment; such as the development of reliable and rapid diagnostic technology by micro-channel PCR chip, quantitative PCR with calibration and antibody test by ELISA, and repositioning of approved drugs as candidates of COVID-19 therapeutic agents by in silico screening.

Coordinator

Dr. Kimihiko Kameyama

Deputy Director General
National Institute of Advanced Industrial Science and Technology

Mission and strategy of our R&D in post-COVID-19 era

Dr. Kimihiko Kameyama

Deputy Director General
The National Institute of Advanced Industrial Science and Technology (AIST)

In Japanese

In silico approaches to drug repositioning for COVID-19

Dr. Takatsugu Hirokawa

Chief Senior Researcher
Cellular and Molecular Biotechnology Reseach Institute

In Japanese

Rapid real-time PCR system for COVID-19 diagnosis

Dr. Hidenori Nagai

Group Leader
Biomedical Reseach Institute

In Japanese

NMIJ's challenges to establish metrological traceability for nucleic acid quantification

Dr. Megumi Kato

Group Leader
National Metrology Institute of Japan (NMIJ)

In Japanese

Smartphone-based Covid-19 IgG ELISA kit and its fully automatic diagnostic device

Dr. Yusuke Fuchiwaki

Senior Researcher
Health and Medical Research Institute

In Japanese

Organizer

Oct.16(Fri.)      10  :  00  ~  11  :  30

F201-202
【O-15】
Pre-Registration required

Global Development of Functional Foods - Japan Food for the World - 

Coordinator

Prof. Teruo Miyazawa

NICHe at Tohoku University

Potential of Functional Food System

Prof. Ryuichi Morishita

Endowed Chair Professor
Department of Clinical Gene Therapy
Osaka University

In Japanese

The current state of development of agricultural products as foods with function claims and the future of health care research through food

Dr. Mari Maeda-Yamamoto

Director of healthcare innovation research
Food Research Institute
National Food and Agriculture Research Organization

In Japanese

Claim of "food" functionality in Japan and challenges for global expansion

Prof. Harunobu Amagase

Specially Appointed Professor
New Industry Creation Hatchery Center (NICHe)
Tohoku University

In Japanese

【S-4】 Chugai Pharmaceutical Co., Ltd.
Pre-Registration required Online Seminar

Digital Transformation of Chugai 

Digital Transformation of Chugai

Ms. Satoko Shisai

Vice President, Head of Digital & IT Supervisory Div.
CHUGAI PHARMACEUTICAL CO., LTD.

In Japanese

Digital Transformation of Chugai-Innovation of drug discovery process by utilizing AI

Dr. Hiroyuki Tsunoda

Head of Discovery Technology Dept.
CHUGAI PHARMACEUTICAL CO., LTD.

In Japanese

Digital Transformation of Chugai-Innovation of drug discovery process by utilizing Real World Data/digital bio marker

Dr. Yoshito Nakanishi

Head of Digital Strategy Dept.
CHUGAI PHARMACEUTICAL CO., LTD.

In Japanese

Oct.15(Thu.)      13  :  30  ~  15  :  00

G303-304
【S-8】 National Institute of Technology and Evaluation
Pre-Registration required

Developing a new frontier in post COVID-19 era
How to accelerate the Bio × Digital transformation in Japan
 

National Institute of Technology and Evaluation

In Japanese

METI 

In Japanese

Chitose Laboratory Corp.

In Japanese

NITE

In Japanese

Organizer

Oct.15(Thu.)      15  :  30  ~  17  :  00

F205-206
【O-13】 Forefront of Digital Health
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)

Forefront of Digital Health 

Coordinator

Dr. Ryo Shimizu

Mitsubishi Tanabe Pharma Corporation

【Recorded Presentation】

Dr. Anil Jina

Activities of the new business in Towa pharmaceutical

Yusuke Amano

Operating Officer Division Manager, Business Development Division
Business Development Division
TOWA PHARMACEUTICAL CO., LTD.

In Japanese

Challenges in Astellas Pharma - Rx+® Business-

Mr. Yuta Watanabe

Senior Vice President, Head of Rx+ Business Accelerator
Rx+ Business Accelerator
Astellas Pharma Inc.

In Japanese

【S-14】 GenScript Japan KK
Pre-Registration required Online Seminar

How Innovative Business Models to Accelerate Cell & Gene Therapy Development 

The market for cell and gene therapy is growing at an exceptional rate globally. Many vendors are making it a priority to develop and launch innovative and breakthrough cell and gene therapy products.

With these great opportunities, researchers still face a lot of challenges and it requires new thinking in operating principles across the entire drug delivery value chain. To overcome challenges and speed up cell and gene therapy development process, a maturing ecosystem is being built for successful biologics market will be quite important. While there are many collaborations are happening between government and many R&D organizations globally, industrial leading marketers or multinational companies are more active to collaborate with smaller companies; there is also a need to have end-to-end manufacturing process worked out early, and CDMO can help a lot.

GenScript/Legend and Janssen has engaged in a strategic collaboration to develop and commercialize a lead product candidate, LCAR-B38M/JNJ-4528, an BCMA-targeted CAR-T cell therapy, give an example to build up an innovative business model. GenScript serves as a key partner in early-stage drug development through its extensive services in gene synthesis and molecular biology, as well as providing end-to-end services to commercialization to accelerate drug development in future.

How Innovative Business Models to Accelerate Cell & Gene Therapy Development

Dr. Brian MIN

CEO
GenScript ProBio
GenScript Japan

Organizer

Oct.14(Wed.)      12  :  00  ~  13  :  30

G301-302
【O-1】
Pre-Registration required

 

Coordinator

Kazuo SHIN-YA

Group Leader
Leading-edge biotechnology research group, Department of Life Science and Biotechnology Biotechnology, Cellular and Molecular Biotechnology Research Institute
National Institute of Advanced Industrial Science and Technology (AIST)

in silico design of biosynthetic pathways with unannotated enzyme genes for chemical production

Naoki Watarai

Chief Executive Officer
digzyme Inc.

In Japanese

Bioproduction AI management System by Using Convolutional Data

Ken Kasahara

Executive Officer
Tech & Biz Development Div.
Chitose Laboratory Corp.

In Japanese

The technology for the heterologous expression and its application for the skeletal modification of middle molecular weight natural products

Kazuo SHIN-YA

Group Leader
Leading-edge biotechnology research group, Department of Life Science and Biotechnology Biotechnology, Cellular and Molecular Biotechnology Research Institute
National Institute of Advanced Industrial Science and Technology (AIST)

Oct.14(Wed.)      15  :  00  ~  17  :  00

F201-202
【S-15】 Cross-ministerial Strategic Innovation Promotion Program(SIP)"Technologies for Smart Bio-industry and Agriculture"
Pre-Registration required

Food connect a susutainable growing society. Aiming to establish a "smart food system" 

To expand the bioeconomy and intensify the competitiveness of biotechnology-related industries in Japan, the program "Technologies for Smart Bio-industry and Agriculture" will contribute to the realization of growing sustainable society by establishing the innovative infrastructure through the integration of the biotechnologies and digital technologies: 1) "Diversified & Sustainable" primary production, 2)Production of biobased materials in sustainable manner, 3)"Medical care & Hearthcare" through "food", and 4)digital transformation. Today, we willl introduce "Production of biobased materials as Resource Circulation".

http://www.naro.affrc.go.jp/laboratory/brain/sip/sip2/index.html

Coordinator

Wataru Mizunashi

Director General, Bioeconomy Unit
Technology Strategy Center
New Energy and Industrial Technology Development Organization

Development of Agri-biomass-based Smart Chemical Production System

Jun-ichiro Hayashi

Professor
Institute for Matrials Chemistry and Engineering
Kyushu University

In Japanese

Development of functional-design and production technologies for innovative bio-materials and products①

Takahito Nakajima

Team Leader
RIKEN

In Japanese

Development of functional-design and production technologies for innovative bio-materials and products②

Yasuo Ohnishi

Professor
The University of Tokyo

In Japanese

Development of an Agri-biomass-based Production System of Useful Protein and Advanced Materials using Silkworm

Hideki Sezutsu

Leader
Institute of Agrobiological Sciences
National Agriculture and Food Research Organization (NARO)

In Japanese

Development of Novel Technology for Bioprocess Optimization in Smart Bio-Industry

Tomohiro Tamura

Director General
Department of Life Science and Biotechnology
National Institute of Advanced Industrial Science and Technology (AIST)

In Japanese

Organizer

Oct.15(Thu.)      9  :  30  ~  11  :  30

F201-202
【O-6】 Transition to a Carbon Neutral and Sustainable Society
Pre-Registration required

Transition to a Carbon Neutral and Sustainable Society 

Coordinator

Prof. Yukari TAKAMURA

Professor
Institute for Future Initiatives, The University of Tokyo

Mr. Tokutaro Nakai

Vice-Minister
Ministry of the Environment,Government of Japan

In Japanese

The role of bioeconomy to realize decarbonized society

Dr. Aikawa Takanobu

Renewable Energy Institute

In Japanese

Redesigning the economy and society to be sustainable and resilient through the transition to a decarbonized society

Mr. Sei Kato

Director, Climate Change Projects Office, Climate Change Policy Division, Global Environment Bureau
MINISTY OF THE ENVIRONMENT GOVERMENT OF JAPAN

In Japanese

Moving businesses and ESG investing toward a decarbonized society

Prof. Yukari Takamura

Professor
Institute for Future Initiatives, The University of Tokyo

Organizer

Oct.15(Thu.)      15  :  30  ~  17  :  00

F203-204
【O-12】 Towards Sustainable Consumption and Production of Plastics
Pre-Registration required

Towards Sustainable Consumption and Production of Plastics  

Coordinator

Dr. Kuniki Kino

Professor
Department of Applied Chemistry, Faculty of Science and Engineering, Waseda University

Corporate Alliance Initiatives for Plastic Recycling

Mr. Koichi Yanagita

Japan Clean Ocean Material Alliance

In Japanese

”Challenge for Innovation Across the Seven & i Group to Realize a "Prosperous and Sustainable Society"”

Ms. Tsuryu Mayumi

Executive officer Senior officer
Corporate communication division Sustainability development department
Seven&i Holdings.Co.,Ltd

In Japanese

Sustainable efforts in Suntory's packages

Mr. Tatsuki Kado

Senior General Manager
Packaging Material Department, Supply Chain Management Division
SUNTORY MONOZUKURI EXPERT LIMITED

In Japanese

ISO standards supporting for developments of new materials and their promotions in market -bio-based content and biodegradability-

Dr. Masao Kunioka

National Institute of Advanced Industrial Science and Technology

In Japanese

Organizer

Oct.14(Wed.)      13  :  00  ~  14  :  30

F205-206
【O-2】
Pre-Registration required

Toward the Promotion of Japan's Bioeconomy Strategy 2020 - Part 1 : About Data Connection Creating Markets - (tentative) 

Coordinator

Dr. Hitoshi Kuboniwa

Chairman
Steering Committee
Japan Bioindustry Association

TBC

Biodata in the digital age

Dr. FUJITA Tomohiro

Founder and Chief executive officer of Chitose Laboratory Corp. / a member of Strategy Council in CABINET SECRETARIAT / Program-Specific Professor in Kyoto University

In Japanese

TBC

TBC

Mr. Noriaki Kobayashi

Director of the Board, Senior Executive Officer / Project Director, Technologies for Smart Bio-industry and Agriculture Project under the Cross-ministerial Strategic Innovation Promotion Program
Kirin Holdings Comapany, Limited

In Japanese

Organizer

Oct.14(Wed.)      14  :  00  ~  16  :  30

G301-302
【A-1】
Pre-Registration required

Japan Bioindustry Award・Bioindustry Research Award 2020 Ceremony and Award Lecture
 

Japan Bioindustry Award Lecture「Therapeutic revolution in hemophilia A by creating a coagulation factor Ⅷ function-mimetic bispecific antibody」

Dr. Takehisa Kitazawa

Department Manager
Discovery Pharmacology Department, Research Division
Chugai Pharmaceutical Co., Ltd.

In Japanese

Development of highly sensitive in vivo bioluminescence imaging technolog

Dr. Satoshi Iwano

Researche
Center for Brain Science
RIKEN

In Japanese

Development of new extraction and separation technologies for environmental-friendly bioindustrial production

Dr. Masaki Ota

Associate Professor
Graduate School of Environmental Studies
Tohoku University

In Japanese

Elucidation of biological function and ecology of insecticide-degrading gut bacteria in pest insects

Dr. Yoshitomo Kikuchi

Senior Researcher
Bioproduction Research Institute
National Institute of Advanced Industrial Science and Technology (AIST)

In Japanese

「Development of raw material production technology for high-performance biomass plastics from renewable resources using microbial fermentation」

Dr. Takeshi Kubota

Senior Researcher
Molecular Microbiology and Biotechnology Group
Research Institute of Innovative Technology for the Earth (RITE)

In Japanese

Highly sensitive nucleic acid detection method towards precise medical diagnosis of infectious diseases and cancers

Dr. Ken Komiya

Assistant Professor
School of Computing
Tokyo Institute of Technology

In Japanese

「Large circular DNA amplification technology by reconstituting chromosome replication cycle」

Dr. Masayuki Su’etsugu

Professor
College of Science
Rikkyo University

In Japanese

Central mechanisms that modulate and transmit gustatory information

Dr. Ken-ichiro Nakajima

Associate Professor
Division of Endocrinology and Metabolis
National Institute for Physiological Sciences

In Japanese

Development of production process for useful compounds based on extensive screening of microbial enzymes

Dr. Ryotaro Hara

Program-Specific Associate Professor
Graduate School of Agriculture,
Kyoto University

In Japanese

Self-organization of hair follicle stem cells and its use for hair regenerative medicine

Dr. Junji Fukuda

Professor
Graduate School of Engineering
Yokohama National University

In Japanese

Bio-adhesive optoelectronics for emerging photodynamic cancer therapy

Dr. Toshinori Fujie

Associate Professor (Lecturer)
School of Life Science and Technology
Tokyo Institute of Technology

In Japanese

Organizer

Oct.15(Thu.)      10  :  00  ~  11  :  30

G303-304
【O-10】
Pre-Registration required

 

Coordinator

Implementation of the Startup Ecosystem into the Lifescience Business

Dr. Koyanagi Tomoyoshi

Head of TR Promotion and Education Center, Professor
Tsukuba Clinical Research and Development Organization (T-CReDO)
University of Tsukuba

In Japanese

TBC

TBC

Expectations of the Global Bio-Community

Dr. FUJITA Tomohiro

Founder and Chief executive officer of Chitose Laboratory Corp. / a member of Strategy Council in CABINET SECRETARIAT / Program-Specific Professor in Kyoto University

In Japanese

Mr. Edward Willems

Industry expectations for the global biocommunity

Ms. SAWADA TAKUKO

Director and Executive Vice President and Senior Vice President of Integrated disease care Department
SHIONOGI & Co., Ltd.

In Japanese

Luncheon

Oct.15(Thu.)      12  :  00  ~  13  :  00

F203-204
【L-2】 Beyond Next Ventures Inc.
Pre-Registration required

The growing importance of shared-labs and shared space community for biotech startups 

Ms. Aki Igarashi

Manager
Beyond Next Ventures Inc.

In Japanese

Beyond Next Ventures Inc.and Biotech startups.

In Japanese